Where Will Bristol Myers Squibb Be in 5 Years?

Investors often look to major pharmaceutical stocks as an area that is likely to provide an anchor for their portfolios. Thanks to their supposedly consistent cash flows, they often appear to be capable of steadily growing in value over time.However, that's not always the case. Even once-stellar companies stumble. Consider Bristol Myers Squibb (NYSE: BMY), which has seen its shares rise just 2% over the past five years, seesawing back and forth over that time. Let's map out its next five years and see if better times lay ahead for the ailing drug giant.Financially speaking, this pharma is not in good condition, which will have a big effect on what it can accomplish over the next five years. Its trailing-12-month operating expenses of $28.2 billion are substantially higher than its operating income of around $7.3 billion over that period.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool